Innovair (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, suppressing inflammatory pathways and decreasing swelling. Formoterol fumarate activates β2‑adrenergic receptors on bronchial smooth muscle, increasing cyclic AMP and causing prolonged bronchodilation. Together they provide anti‑inflammatory and bronchodilatory effects for better airway control.

The dose of Innovair is individualized by the prescribing clinician based on disease severity, age, and response to therapy. Typically, patients inhale a fixed number of puffs twice daily, but exact dosing and frequency must be determined by a qualified healthcare professional.

Safety data for Innovair in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To order Innovair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Innovair combines an inhaled corticosteroid and a long‑acting β2‑agonist in a single device, offering convenience over separate inhalers. Compared with single‑component products, it provides both anti‑inflammatory and bronchodilator actions, which can improve adherence. Its efficacy and safety profile are similar to other approved ICS/LABA combinations, but choice may depend on device preference, dosing schedule, and individual patient response.

Innovair should be stored below 25 °C in its original packaging, protected from moisture and direct heat. Keep the inhaler cap tightly closed when not in use. Do not expose the device to freezing temperatures or extreme humidity, and avoid cleaning the mouthpiece with solvents; a dry cloth is sufficient.

Innovair is delivered via inhalation using a metered‑dose inhaler. The patient should shake the inhaler gently, exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the device. Holding the breath for about 10 seconds after inhalation maximizes drug deposition. A spacer can be used to reduce oropharyngeal exposure.

Serious risks include paradoxical bronchospasm, adrenal suppression with prolonged high‑dose use, reduced bone mineral density, severe allergic reactions such as anaphylaxis, and cardiac effects like tachycardia or arrhythmias. Patients should seek immediate medical attention if they experience sudden worsening of breathing, severe palpitations, or signs of an allergic reaction.

Innovair is contraindicated in individuals with known hypersensitivity to beclometasone dipropionate, formoterol fumarate, or any excipients in the inhaler. It should also be avoided in patients who have experienced a severe hypersensitivity reaction to other inhaled corticosteroid/LABA combinations. Caution is advised for patients with uncontrolled cardiovascular disease, severe arrhythmias, or active infections.